Bob Bradway, Amgen CEO (Scott Eisen/Bloomberg via Getty Images)
July 27, 2021 04:47 PM EDTUpdated 05:04 PM
Deals

Am­gen bel­lies back up to the M&A ta­ble for an­oth­er biotech buy­out, this time with a $2.5B deal for an an­ti­body play­er fo­cused on PS­MA

John Carroll

Editor & Founder

Five months af­ter Am­gen CEO Bob Brad­way stepped up to the M&A ta­ble and ac­quired Five Prime for $1.9 bil­lion, fol­low­ing up with the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

RFK Jr. says his opin­ions of vac­cines are ‘ir­rel­e­vant.’ For­mer FDA chief Califf dis­agrees

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

A service from the Financial Times